ニュース

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host

The biotech's innovative platform could pay off.

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Before you decide whether CRISPR Therapeutics stock looks attractive at around US$52.38, it helps to ask a simple question: what are you actually paying for compared with what the business might be worth? Over the last week the stock return is 0.6%, over the last month it is 5.8%, and over the last year it is 58.0%, while the year-to-date return is a 2.6% decline and the three- and five-year returns are 17.4% and 49.4% declines respectively, which may catch the eye of both momentum fans and...

Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.

CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -12.39% and -82.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

The biotech's candidate may treat a great number of illnesses that have one thing in common.

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for Casgevy, the gene therapy it co-commercializes with Vertex Pharmaceuticals. An interesting angle for investors is how Casgevy’s early commercial uptake and growing treated-patient base may influence perceptions of CRISPR Therapeutics’ broader gene-editing platform and revenue potential. With the...

CRISPR Therapeutics AG (CRSP) reached $50.71 at the closing of the latest trading day, reflecting a -2.59% change compared to its last close.

These stocks come with risk, but they also have some exciting long-term growth opportunities.

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $52.06, representing a +2.1% change from its previous close.